Sysmex (OTCMKTS:SSMXY) Issues Quarterly Earnings Results

Sysmex (OTCMKTS:SSMXY) released its quarterly earnings data on Friday. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.02, Zacks reports. The company had revenue of $825.85 million for the quarter, compared to analyst estimates of $739.25 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex updated its FY 2026 guidance to 0.382-0.382 EPS.

Sysmex Stock Up 6.2%

SSMXY opened at $10.94 on Friday. The stock’s fifty day simple moving average is $9.38 and its 200 day simple moving average is $9.08. Sysmex has a 1-year low of $8.01 and a 1-year high of $14.20. The stock has a market cap of $6.89 billion, a PE ratio of 28.79 and a beta of 1.05. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.